-+ 0.00%
-+ 0.00%
-+ 0.00%
Medicenna reports bizaxofusp more than doubles median survival versus external control in glioblastoma subgroup
Share
Listen to the news
Medicenna reports bizaxofusp more than doubles median survival versus external control in glioblastoma subgroup
  • Medicenna Therapeutics reported longer survival with bizaxofusp versus a matched external control in Phase 2b patients with inoperable recurrent glioblastoma.
  • Results were presented at the Society for Neuro-Oncology annual meeting, held November 12-15, 2026, in Philadelphia.
  • The strongest benefit appeared in high-dose patients matching the planned Phase 3 population; the small, nonrandomized comparison requires confirmation.
  • A proposed pivotal trial would compare single-dose bizaxofusp with a hybrid control combining randomized standard care and matched external patients.
  • The FDA agreed the hybrid control approach was feasible for the planned pivotal study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicenna Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160700PRIMZONEFULLFEED9878195) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending